26 related articles for article (PubMed ID: 3948195)
1. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of mitolactol in previously treated and untreated patients with advanced colorectal cancer: an Illinois Cancer Council trial.
Locker GY; Lanzotti V; Sweet D; Lad T; Khandekar J; Stiff P; Johnson C; Miller S
Cancer Treat Rep; 1984 Oct; 68(10):1303-4. PubMed ID: 6525605
[No Abstract] [Full Text] [Related]
3. Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
Locker GY; Khandekar J; Krauss S; Reisel H; Hoeltgen T; Wolter J; Haid M; Hoffman R; Blough R; Johnson C
Cancer Treat Rep; 1987 Jun; 71(6):649-50. PubMed ID: 3555791
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
[No Abstract] [Full Text] [Related]
5. Phase II study of VM-26 in adult malignancies.
Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
[No Abstract] [Full Text] [Related]
6. Phase II trial of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial.
Locker GY; Kilton L; Hoeltgen T; Knop RH; Benson AB; Chernicoff D; Barrett J; Blough R; Johnson C
Cancer Treat Rep; 1987 Sep; 71(9):871-2. PubMed ID: 2957053
[No Abstract] [Full Text] [Related]
7. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
[No Abstract] [Full Text] [Related]
8. Teniposide: a review of 12 years of experience.
O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
[No Abstract] [Full Text] [Related]
9. VM26: phase I and II studies.
Macbeth FR
Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
[No Abstract] [Full Text] [Related]
10. A phase II study with teniposide (VM26) in patients with progressed or relapsed small cell lung cancer (SCLC).
Tummarello D; Guidi F; Di Furia L; Gramazio A; Menichetti E; Cellerino R
J Chemother; 1989 Feb; 1(1):64-7. PubMed ID: 2542470
[TBL] [Abstract][Full Text] [Related]
11. The podophyllotoxin derivatives VP16-213 and VM26.
Issell BF
Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
[TBL] [Abstract][Full Text] [Related]
12. Podophyllotoxin derivatives.
D'Incalci M; Garattini S
Cancer Chemother Biol Response Modif; 1991; 12():75-81. PubMed ID: 1931460
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
